methyl 3,3,3-trifluoro-N-(hept-6-en-1-yl)-L-alanyl-(4R)-4-{[(4-ethenyl-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy}-L-prolinate | 1179843-53-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 3,3,3-trifluoro-N-(hept-6-en-1-yl)-L-alanyl-(4R)-4-{[(4-ethenyl-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy}-L-prolinate
• 英文别名: [(3R,5S)-5-methoxycarbonyl-1-[(2R)-3,3,3-trifluoro-2-(hept-6-enylamino)propanoyl]pyrrolidin-3-yl] 4-ethenyl-1,3-dihydroisoindole-2-carboxylate
• CAS: 1179843-53-8
• 化学式: C₂₇H₃₄F₃N₃O₅
• 分子量: 537.579
• InChiKey: DPYYLYBPKMQVDY-AKIFATBCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  88.2
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 3,3,3-trifluoro-N-(hept-6-en-1-yl)-L-alanyl-(4R)-4-{[(4-ethenyl-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy}-L-prolinate 在 詹氏钌催化剂-1 作用下， 以 二氯甲烷 为溶剂， 以12%的产率得到methyl (5R,7S,10R,17E)-3,9-dioxo-10-(trifluoromethyl)-6,7,9,10,11,12,13,14,15,16-decahydro-1H,5H-2,22:5,8-dimethano-4,2,8,11-benzoxatriazacycloicosine-7(3H)-carboxylate
  参考文献：
  名称：

  Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2−P4 Macrocycles

  摘要：

  In a follow-Lip to our recent disclosure of P2-P4 macrocyclic inhibitors of the hepatitis C virus (HCV) NS3 protease (e.g., 1, Chart 1), we report a new but related compound series featuring a basic amine at the N-terminus of the P3-amino acid residue. Replacement of the electroneutral P3-amino acid capping group (which is a feature of almost all tripeptide-like inhibitors of NS3 reported to date) with a basic group is not only tolerated but can result in advantageous cell based potency. Optimization of this new class of P3-amine based inhibitors gave compounds such as 25 and 26 that combine excellent cell based activity with pharmacokinetic properties that are attractive for an antiviral targeting HCV.

  DOI：

  10.1021/jm900372w
• 作为产物：
  描述：

  1-烯庚醛 、 methyl 3,3,3-trifluoroalanyl-(4R)-4-{[(4-ethenyl-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy}-L-prolinate 在 sodium cyanoborohydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以17%的产率得到methyl 3,3,3-trifluoro-N-(hept-6-en-1-yl)-L-alanyl-(4R)-4-{[(4-ethenyl-1,3-dihydro-2H-isoindol-2-yl)carbonyl]oxy}-L-prolinate
  参考文献：
  名称：

  Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2−P4 Macrocycles

  摘要：

  In a follow-Lip to our recent disclosure of P2-P4 macrocyclic inhibitors of the hepatitis C virus (HCV) NS3 protease (e.g., 1, Chart 1), we report a new but related compound series featuring a basic amine at the N-terminus of the P3-amino acid residue. Replacement of the electroneutral P3-amino acid capping group (which is a feature of almost all tripeptide-like inhibitors of NS3 reported to date) with a basic group is not only tolerated but can result in advantageous cell based potency. Optimization of this new class of P3-amine based inhibitors gave compounds such as 25 and 26 that combine excellent cell based activity with pharmacokinetic properties that are attractive for an antiviral targeting HCV.

  DOI：

  10.1021/jm900372w

文献信息

• Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2−P4 Macrocycles
  作者：Steven Harper、Marco Ferrara、Benedetta Crescenzi、Marco Pompei、Maria Cecilia Palumbi、Jillian M. DiMuzio、Monica Donghi、Fabrizio Fiore、Uwe Koch、Nigel J. Liverton、Silvia Pesci、Alessia Petrocchi、Michael Rowley、Vincenzo Summa、Cristina Gardelli

  DOI：10.1021/jm900372w

  日期：2009.8.13

  In a follow-Lip to our recent disclosure of P2-P4 macrocyclic inhibitors of the hepatitis C virus (HCV) NS3 protease (e.g., 1, Chart 1), we report a new but related compound series featuring a basic amine at the N-terminus of the P3-amino acid residue. Replacement of the electroneutral P3-amino acid capping group (which is a feature of almost all tripeptide-like inhibitors of NS3 reported to date) with a basic group is not only tolerated but can result in advantageous cell based potency. Optimization of this new class of P3-amine based inhibitors gave compounds such as 25 and 26 that combine excellent cell based activity with pharmacokinetic properties that are attractive for an antiviral targeting HCV.